Akili, Inc. Common Stock/AKLI

$0.25

2.51%
-
1D1W1MYTD1YMAX

About Akili, Inc. Common Stock

Akili, Inc. is a digital medicine company engaged in the development of cognitive treatments through technologies. The Company’s approach of developing and commercializing technologies is designed to directly target the physiology of the brain. Its therapeutic engines are designed to target cognitive functions with the potential to address multiple medical conditions presenting the same functional cognitive impairments. Its product, EndeavorRx, is indicated for use to improve attention function for children ages 8-17 with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. Its product, EndeavorOTC, which is built on the same platform as EndeavorRx, nationwide without a prescription to improve attention function, ADHD symptoms and quality of life in adults 18 years of age and older with primarily inattentive or combined type ADHD. In addition, the Company has several investigator-initiated studies.

Ticker

AKLI

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

W. Martucci

Employees

68

Headquarters

Boston, United States

AKLI Metrics

BasicAdvanced
$18.01M
Market cap
-
P/E ratio
-$0.76
EPS
-
Beta
-
Dividend rate
$18.01M
$1.67
$0.19
2.4M
6.018
9.395
22.208
-27.18%
-52.9%
-70.32%
-59.98%
10.731
0.307
0.308
419.5%
-211.78%
-24.76%

What the Analysts think about AKLI

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 1 analyst.
160% upside
High $0.65
Low $0.65
$0.25
Current price
$0.65
Average price target

AKLI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,585.71% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$700K
0%
Net income
$-11.1M
-29.75%
Profit margin
-1,585.71%
-29.75%

AKLI Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 5.26%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.17
-$0.16
-$0.18
-
-
Expected
-$0.22
-$0.20
-$0.19
-$0.21
-$0.14
Surprise
-21.11%
-20.99%
-5.26%
-
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Akili, Inc. Common Stock stock?

Akili, Inc. Common Stock (AKLI) has a market cap of $18.01M as of April 25, 2024.

What is the P/E ratio for Akili, Inc. Common Stock stock?

The price to earnings (P/E) ratio for Akili, Inc. Common Stock (AKLI) stock is 0 as of April 25, 2024.

Does Akili, Inc. Common Stock stock pay dividends?

No, Akili, Inc. Common Stock (AKLI) stock does not pay dividends to its shareholders as of April 25, 2024.

When is the next Akili, Inc. Common Stock dividend payment date?

Akili, Inc. Common Stock (AKLI) stock does not pay dividends to its shareholders.

What is the beta indicator for Akili, Inc. Common Stock?

Akili, Inc. Common Stock (AKLI) does not currently have a Beta indicator.

What is the Akili, Inc. Common Stock stock price target?

The target price for Akili, Inc. Common Stock (AKLI) stock is $0.65, which is 160% above the current price of $0.25. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Akili, Inc. Common Stock stock

Buy or sell Akili, Inc. Common Stock stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing